NuGen Medical Devices Inc. announced the Mexican government has completed the registration of NuGen's needle-free InsuJet?? injection device for sale throughout the country as a medical device. In May 2023, NuGen received its first bulk purchase order from Science-Link Trading SAPI de CV ("Science-Link"), a health and wellness company in Mexico, for the Mexican market for 500 units of the Company's needle-free Insu Jet??

injection device, followed by an additional 2,000 units and consumables. The purchase order for the 500 InsuJet?? devices is now paid in full and delivery is anticipated during Fourth Quarter 2023.

NuGen is pleased to further report its distribution agreement with Science-Link targets the sale of approximately 5,000 needle-free injectors in 2024. At target, the total transaction value for 2023 and 2024 orders is estimated to have a lifetime value of USD 6.2 million to 2027 as previously reported by the Company on June 2, 2023. Mexico is a large diabetes market globally as an estimated 1 in 6 adults are now living with diabetes1.

In 2021, the estimated adult diabetic population grew to 14 million patients - a rise of 10% in the last 2 years. Diabetes-related health expenditure in Mexico has reached USD 20 billion, putting it in the top ten countries or territories with the total health expenditure2.